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Abstract 
Pathogenic variants in ZMYND11, which acts as a transcriptional repressor, have been 
associated with intellectual disability, behavioural abnormalities and seizures. Only 
11 affected individuals have been reported to-date, and the phenotype associated with 
pathogenic variants in this gene have not been fully defined.  
Here, we present 16 additional patients with predicted pathogenic heterozygous 
variants in ZMYND11, including four individuals from the same family, to further 
delineate and expand the genotypic and phenotypic spectrum of ZMYND11-related 
syndromic intellectual disability. The associated phenotype includes developmental 
delay, particularly affecting speech, mild-moderate intellectual disability, significant 
behavioural abnormalities, seizures, and hypotonia. There are subtle shared 
dysmorphic features, including prominent eyelashes and eyebrows, depressed nasal 
bridge with bulbous nasal tip, anteverted nares, thin vermilion of the upper lip and 
wide mouth. Novel features include brachydactyly and tooth enamel hypoplasia. 
Most identified variants are likely to result in premature truncation and/or nonsense 
mediated decay. Two ZMYND11 variants located in the final exon - p.(Gln586*) 
(likely escaping nonsense-mediated decay) and p.(Cys574Arg) - are predicted to 















disrupt the MYND-type zinc finger motif and likely interfere with binding to its 
interaction partners. Hence, the homogeneous phenotype likely results from a 
common mechanism of loss-of-function. 
Keywords: Gene Expression Regulation, Intellectual Disability, Seizures, Zinc 
Fingers, Behavioral Symptoms 
Introduction 
The chromosome 10p15.3 microdeletion syndrome is characterised by developmental 
delay (DD) and intellectual disability (ID), craniofacial dysmorphism, behavioural 
abnormalities, hypotonia, and seizures (DeScipio et al., 2013). Haploinsufficiency of 
ZMYND11 (NCBI Gene ID: 10771) is believed to account for many of the features 
associated with chromosome 10p15.3 microdeletion (Tumiene et al., 2017). 
ZMYND11 has been shown to act as a transcriptional repressor by inhibiting the 
elongation phase of RNA Polymerase II by recognizing histone modification present 
in transcribed regions, specifically H3K36 trimethylation (Wen et al., 2014). 
In support of the critical role of ZMYND11 in the chromosome 10p15.3 microdeletion 
syndrome, patients with de novo truncating variants in ZMYND11 have a similar 
phenotype, including ID, seizures, and behavioural issues (Coe, Witherspoon, 
Rosenfeld, van Bon, et al., 2014; Popp et al., 2017). In addition, missense variants in 
this gene have also been associated with ID and seizures, although there is a more 
severe phenotype in patients with specific variants, which may be related to a gain-of-
function mechanism (Cobben et al., 2014; Moskowitz et al., 2016). A splice site 
variant has also been reported in a child with autism spectrum disorder (Iossifov et al., 
2012). In total, 11 patients with pathogenic variants in ZMYND11 (MIM# 616083) 
have been reported to date (Aoi et al., 2019; Cobben et al., 2014; Coe, Witherspoon, 















Rosenfeld, Van Bon, et al., 2014; Iossifov et al., 2012; Moskowitz et al., 2016; Popp 
et al., 2017). 
Here, we present 16 previously unreported individuals with pathogenic variants in 
ZMYND11, including four from the same family. We further delineate and expand the 
genotype-phenotype correlations and phenotypic spectrum of ZMYND11-related 
intellectual disability.  
Methods 
All patients were ascertained after routine referral to their local Clinical Genetics 
service. Patients 1, 3, 5 and 8 were gathered through international collaboration using 
GeneMatcher (Sobreira, Schiettecatte, Valle, & Hamosh, 2016). Patients 2, 6, 7, 9, 11 
and 12 were identified through the Wellcome Trust Deciphering Developmental 
Disorders study (Wright et al., 2015). Patients 13-15 were identified as affected 
relatives of patient 12. Patients 4, 10 and 16 were identified through personal 
communication. Exome sequencing was performed on all probands, with a trio 
approach on patients 1, 3, 5, 6, 9-12, and 16; a duo approach on patients 2, 4, 7, and 8, 
as DNA samples were only available from one parent. Sanger sequencing only was 
used to ascertain the presence of the familial variant in patients 13-15, and all other 
patients had their ZMYND11 variant confirmed using this method. All sequence 
variants were described with reference to ZMYND11 transcript NM_006624.5. All 
variants were classified according to the American College of Medical Genetics 
(ACMG) guidelines (Richards et al., 2015). Further information is available in the 
supplemental data. Patient variants have been uploaded to either ClinVar 
(https://www.ncbi.nlm.nih.gov/clinvar/), Global Variome shared LOVD 
http://www.lovd.nl, or DECIPHER (https://decipher.sanger.ac.uk). 

















16 individuals (including 13 probands and two additional children of one affected 
mother) had a predicted pathogenic variant in ZMYND11. Of these, eight were de 
novo, one was inherited by three sibs from their affected mother, one was paternally-
inherited, and three were of unknown inheritance. Ten variants were predicted to 
result in protein truncation, two were missense, and one affected a splice site (Table 
1). None of the variants in this series were present in the gnomAD database (v2.1.1) 
(Karczewski et al., 2019). Of the two missense variants, one was located in a zinc 
finger domain (c.1720T>C; p.(Cys574Arg)), and the other was not in a known 
functional domain (c.1246G>A; p.(Glu416Lys)). Further information is available in 
the supplemental data.  
Patient phenotypes 
Phenotypic information for all patients is shown in Table 1 In-depth patient 
summaries are available in the supplemental data (Supp. Patient Summaries). 
Prominent phenotypic features are detailed below. The denominators refer to the 
number of patients for whom the specific information is available. 
Birth weight was at or above the 98
th
 centile in three patients (3/14; 21%). Feeding 
problems (e.g. excess vomiting after feeds, bottle feeding requiring more than one 
hour), were present in 6/13 patients (46%). Most patients had normal growth 
parameters and head circumference.  
Development was delayed in all patients (14/14; 100%). The median age at 
independent walking was 24 months (with age range of 17 months to four years). 















Three patients remained unable to walk at the ages of two-and-a-half (for two 
individuals) and four years, respectively. Speech delay was prominent, with 14/14 
(100%) affected. First words were achieved at a median age of two-and-a-half years 
(with age range of two years to four years). Two patients were non-ambulatory, and 
had not achieved speech at two-and-a-half and four years age respectively (2/14; 
14%). All patients had mild to moderate intellectual disability (13/13; 100%).  
Almost all patients had behavioural issues (14/16; 88%). These include attention 
deficit, hyperactivity and impulsivity (8/16; 50%), aggressive behaviour (8/16; 50%), 
and autism spectrum disorder or autistic traits (3/15; 20%). Neurological 
abnormalities were detected in 10/16 (63%); mostly hypotonia (5/16; 31%) and 
epilepsy (5/16; 31%).  
Photographs of patients in this series are shown in Fig. 1. Dysmorphic facial features 
were judged to be present in 11/16 (69%). There were a number of shared facial 
features, including thick eyebrows, prominent eyelashes, depressed nasal bridge with 
bulbous nose, anteverted nares, thin vermilion of the upper lip and wide mouth.  
Patients 12-14 in this series inherited their ZMYND11 variant from their mother 
(patient 15). All individuals in this family had special educational needs; two of the 
siblings are now in employment. The ZMYND11 variant found in Patient 9 was 
paternally inherited. Detailed phenotypic information is not available for the father.  
Discussion 
Here, we present 16 new individuals with predicted pathogenic variants in ZMYND11. 
Comparison with all previously published patients allows further delineation of the 
phenotypic spectrum associated with mutations in this gene (Table 2) (Supp. Table 















S1) (Aoi et al., 2019; Cobben et al., 2014; Coe, Witherspoon, Rosenfeld, van Bon, et 
al., 2014; Iossifov et al., 2012; Moskowitz et al., 2016; Popp et al., 2017).  
All patients (including our series) had developmental delay, particularly affecting 
speech, and ID. The severity of ID in this series is mild to moderate, but four patients 
have previously been described with severe ID (Cobben et al., 2014; Coe, 
Witherspoon, Rosenfeld, van Bon, et al., 2014; Moskowitz et al., 2016; Popp et al., 
2017). Behavioural issues are also a prominent feature both in our series and in those 
previously published (Coe, Witherspoon, Rosenfeld, van Bon, et al., 2014; Popp et al., 
2017), including aggression, attention deficit/hyperactivity, and autism/autistic traits. 
Therefore, this series provides further evidence that behavioural abnormalities are a 
significant part of the ZMYND11-associated phenotype. These behavioural problems 
may pose a substantial psychosocial burden, especially if the intellectual disability is 
mild. Hypotonia and epilepsy affect 48% and 39% of all patients, respectively 
(including our series). This enables us to indisputably establish hypotonia and 
epilepsy as part of the phenotype associated with this syndrome.  
Dysmorphic features, particularly thick eyebrows, prominent eyelashes and a bulbous 
nose, are present in the majority of patients (Fig. 1). These are in line with the patients 
reported by Coe et al., (2014). These dysmorphisms may prove useful with regard to 
reverse phenotyping. Feeding difficulties were present in 59% of all patients 
(including our series), although only three patients required supplementary feeding. 
Brachydactyly, seen in two patients in our series, is a possible novel feature. 
Interestingly, tooth enamel hypoplasia, present in one patient in our series, has 
previously been reported in another patient with a ZMYND11 variant (Coe, 
Witherspoon, Rosenfeld, van Bon, et al., 2014), indicating this may be a rare and/or 















overlooked phenotypic feature, although formal dental assessment has not been 
documented for most patients.  
In this series, three individuals inherited a predicted pathogenic ZMYND11 variant 
from their affected mother; another patient inherited the pathogenic variant from his 
father on whom detailed phenotypic information was lacking. Inheritance of a 
pathogenic ZMYND11 variant from an affected parent has been previously reported 
(Coe et al. 2014). Familial inheritance should therefore be considered in variant 
filtering and interpretation and reproductive counselling.  
The majority of patients, including those in our series, have truncating variants, which 
are likely subject to nonsense-mediated decay and hence, result in haploinsufficiency 
(Fig. 2). Of note, the p.(Gln586*) variant in our series is located in the last exon and 
therefore may escape nonsense-mediated decay. The p.(Cys574Arg) variant is 
similarly located in the last exon. These variants may be expected to have a 
deleterious effect through disruption of the MNYD-type zinc finger motif. This motif 
interacts with a number of intracellular partners, for example the NCoR 
transcriptional corepressor (Masselink & Bernards, 2000), and amino acid variation 
within this motif has been shown to disrupt binding of these partners, resulting in 
reduced efficacy of ZMYND11-mediated transcriptional repression (Kateb et al., 
2013; Masselink & Bernards, 2000). We suspect, therefore, that the two variants 
affecting the MYND-type zinc finger motif domain in our series will at least result in 
a reduced function of the protein. The phenotype of these patients and a previously 
reported individual (Coe et al. 2014) with a p.(Gln587del) variant in this motif is not 
notably different to those patients harbouring variants causing haploinsufficiency, 
supporting a loss-of-function mechanism. The p.(Glu416Lys) variant in this series is 















not in a functional domain. It has been classified as likely pathogenic given that it is 
de novo and not present in the gnomAD database; however further research is 
required to determine the effect of this variant.  
In contrast, two missense pathogenic variants have been reported in patients with 
notably different phenotypes to those in this series. The p.(Ser421Asn) variant 
resulted in a severe Angelman-like phenotype, and the p.(Arg600Trp) variant caused 
distinct facial dysmorphism, moderate to severe intellectual disability, and short 
stature (Cobben et al., 2014; Moskowitz et al., 2016). Given these distinct phenotypes, 
it is possible that other mechanisms, including a gain-of-function, may be at play, but 
further research is required to characterise the effects of these specific variants.  
Conclusions 
We present a series of 16 patients with predicted pathogenic ZMYND11 variants, 
predicted to result in haploinsufficiency or reduced protein function, together with a 
review of the published literature, allowing further delineation of the associated 
phenotype. Developmental delay and ID, usually mild to moderate, are universally 
present. Behavioural issues are frequent, and hypotonia and seizures are common. 
Feeding difficulties occur, but are usually mild. Subtle dysmorphism includes 
prominent eyelashes and eyebrows. Novel features include brachydactyly and tooth 
enamel hypoplasia. Our data will contribute to successful reverse phenotyping 
following genomic sequencing. 
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Figures 
Figure 1.  
Photographs of patients in this series. Patient ages are as follows (y- years; mo – 
months): 1 – 3y, 2 – 8y, 3 – 5y 10mo, 4 – 8y, 6 – 4y, 7 – 13y 8mo, 9 – 8y, 10 – 2y 
7mo, 11 – 15y, 12 – 17y, 13 – 22y, 14 – 20y, 15 – 47y, 16 – 2.5y. Note shared 
dysmorphic features (particularly in patients 1, 3-14 and 16) including prominent 
eyelashes and flattened nasal bridge with bulbous nasal tip.  
 
  















Figure 2.  
ZMYND11 protein showing pathogenic variants in this series (below protein) and 
previously reported (above protein) (Cobben et al., 2014; Coe, Witherspoon, 
Rosenfeld, van Bon, et al., 2014; Iossifov et al., 2012; Moskowitz et al., 2016; Popp et 
al., 2017) (transcript NM_006624.5, Human Genome Build GRCh37.p13). Functional 
domains are labelled according to their location in the protein. The tandem PWWP 
(Pro-Trp-Trp-Pro)-Bromo domains function in recognising H3K36 trimethylation. 
 
Table 1. Genotypic and phenotypic data for patients in this series, ordered according 
to likely pathogenic mechanism. Totals include only those patients for whom the 
presence or absence of the feature is reported. Mutation nomenclature according to 
Human Genome Variation Society (HGVS) recommendations 
(http://varnomen.hgvs.org/). All variants were analysed according to transcript 
NM_006624.5. American College of Medical Genetics and Genomics sequence 
interpretation criteria according to Richards et al., 2015.  
Proposed 
pathogenic 
mechanism Haploinsufficiency: NMD   
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Table 2. Genotypic and phenotypic data for all previously reported patients with 
ZMYND11 variants, ordered according to likely pathogenic mechanism, with 
summary total including this series. Totals include only those patients for whom the 
presence or absence of the feature is reported. Mutation nomenclature according to 
Human Genome Variation Society (HGVS) recommendations 
(http://varnomen.hgvs.org/). All variants were analysed according to transcript 
NM_006624.5. American College of Medical Genetics and Genomics sequence 
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